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RANKLAbstract Aim of the work: To evaluate the levels of osteoprotegerin (OPG) and receptor activator
of the nuclear factor jB ligand (RANKL), in patients with rheumatoid arthritis (RA) and to study
the relation between these parameters and bone mineral density (BMD) and disease activity; thus,
investigating the possible role of the OPG/RANKL system in RA related bone loss.
Patients and methods: Fifty patients with RA and 20 age and sex matched healthy controls were
enrolled in the study. BMD of the non-dominant forearm, lumbar spine (L1–4) and proximal
femur, including femoral neck, Wards triangle and greater trochanter was assessed using dual-
energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were measured by ELISA
method.
Results: Rheumatoid arthritis patients had a higher incidence of osteoporosis (23/50, 46%) than
that in healthy controls (3/20, 15%). They displayed lower BMD values than controls at positions
of all detected regions. Compared with healthy controls, RA group showed signiﬁcantly higher
serum levels of RANKL (4.7 ± 3.3 vs. 3.0 ± 3.1 ng/dl, p= 0.001), lower serum levels of OPG
(331.2 ± 143.6 vs. 535.8 ± 229.1 pg/ml, p= 0.001) and OPG/RANKL ratio (531.6 ± 149.4 vs.
882.8 ± 148.6, p= 0.001).
Conclusions: These data suggest that, in RA patients, changes of the OPG/RANKL system
resulting in increased RANKL and decreased OPG in peripheral blood could contribute to the bone
loss characteristic and the generation of osteoporosis in these patients.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Bone loss and bone erosions are chief unsolved problems in
rheumatoid arthritis (RA), a common inﬂammatory autoim-
mune disease characterized by chronic synovitis in joints.
The skeletal complications of RA consist of focal erosion of
marginal and subchondral bone, juxta-articular osteoporosis
and generalized bone loss with reduced bone mass [1].
Osteoclasts were clariﬁed as one of the pivotal effector cells
in the pathogenesis of osteoporosis. Investigations also showed
that profuse generation and activation of osteoclasts might
correlate with joint cartilage and bone destruction in RA [2].
Function of osteoclasts is mainly controlled by a balance
between Tumor Necrosis Factor superfamily molecules: osteo-
protegerin/osteoclastogenesis inhibitory factor (OPG/OCIF),
receptor activator of the nuclear factor jB ligand (RANKL),
receptor activator of the NFjB (RANK), and TNF-related
apoptosis-inducing ligand (TRAIL) [3].
RANKL which originates from the surface of osteoblasts
that bind to RANK, plays a key role in the promotion of
osteoclastogenesis, osteoclast maturation and activation and
prevention of the apoptosis of osteoclastic cells [4]. Interaction
between RANK and RANKL ﬁnally leads to enhanced bone
resorption and bone loss [5]. Activity of RANKL, is the essen-
tial factor in the progression of bone damage in inﬂammatory
joint diseases and determines extent of bone destruction
mediated by osteoclasts [6]. The effects of RANKL can be
neutralized by its decoy receptor OPG, which plays a signiﬁ-
cant inhibitory role in the regulation of osteoclastic bone
resorption [7].
In a recent study it has been proved that patients with RA
showed obviously lower plasma levels of OPG and high
plasma levels of RANKL compared with controls, with a con-
sequent signiﬁcantly lower OPG/RANKL ratio and lower
bone mineral density (BMD) values than controls [8].
The aim of the present work was to evaluate the levels of
OPG and RANKL in RA patients and to study the relation
between these parameters, the BMD and disease activity; thus,
investigating the possible role of the OPG/RANKL system in
RA related bone loss.2. Patients and methods
Fifty rheumatoid arthritis patients were included in this study.
They were consecutively recruited from the Rheumatology
departments at Beni-Sweif and Fayoum University Hospitals
during a period of six months from January to June 2012.
Patients were diagnosed according to the 2010 ACR/EULAR
criteria [9]. Twenty age and sex matched healthy subjects were
recruited as controls for BMD, serum OPG, serum RANKL
and OPG/RANKL ratio. The study was approved by the local
ethics committee in accordance with the declaration of Hel-
sinki ethical standards. Informed consent was obtained from
all patients and controls for inclusion in the study.
Demographic data and disease history taking regarding
onset, duration, course, progression and associated diseases
were obtained from all patients. Number of painful joints
(28 joint count) and numerical rating scale of pain (ranged
from 0 to 10 as 0 means that there is no pain, 10 means that
it is the worst possible pain patient had felt) were evaluated
and disability was assessed by a validated Arabic versionof the Health Assessment Questionnaire (HAQ) – disability
index [10].
History of drug intake mainly steroids (calculating the
cumulative dose), methotrexate (MTX), calcium, Vitamin D
and anti-resorptive drugs were recorded. Thorough clinical
examination of the musculoskeletal system was carried out.
Body mass index (kg/m2) was calculated to all participants.
Number of swollen joints was calculated. Assessment of dis-
ease activity was performed by the modiﬁed disease activity
score in 28 joints (DAS-28) [11].
The following was done for all patients and controls:-Com-
plete blood count (CBC), erythrocyte sedimentation rate
(ESR): by Westergren method, C-reactive protein (CRP), urine
analysis, full blood chemistry, including renal and liver func-
tion tests, serum calcium (total and ionized), phosphorus and
alkaline phosphatase level. Rheumatoid factor (RF IgM, U/
L) was measured for all patients by agglutination slide for
qualitative determination of RF in serum and in case of RF
negative patients we measured anti-cyclic citrullinated peptide
(ant-CCP) antibodies in patient sera.
Sample collection and detection of serum OPG and
RANKL: Blood samples were collected from patients and con-
trols; separated and frozen immediately after blood drawing.
All sera were stored at 20 C until analysis. Serum concen-
trations of OPG and RANKL were measured using ELISA
kits according to the manufacturer’s instructions.
Test principle for OPG assay: Boster’s human OPG ELISA
Kit (Boster Biological Technology, Ltd.) was based on stan-
dard sandwich enzyme-linked immune-sorbent assay technol-
ogy. Human OPG speciﬁc-speciﬁc polyclonal antibodies were
precoated onto 96-well plates. The human speciﬁc detection
polyclonal antibodies were biotinylated. The test samples
and biotinylated detection antibodies were added to the wells
subsequently and then followed by washing with PBS or
TBS buffer. Avidin–Biotin–Peroxidase Complex was added
and unbound conjugates were washed away with PBS or
TBS buffer. HRP substrate TMB was used to visualize HRP
enzymatic reaction. TMB was catalyzed by HRP to produce
a blue color product that changed into yellow after adding
acidic stop solution. The density of yellow is proportional to
the human OPG amount of sample captured in plate.
Test principle for RANKL assay: The ELISA is based on
the competitive binding enzyme immunoassay technique.
(Wuhan ElAab Science Co., Ltd.) The microtiter plate pro-
vided in this kit has been pre-coated with an antibody speciﬁc
to RANKL. During the reaction, RANKL in the sample or
standard competes with a ﬁxed amount of biotin-labeled
RANKL for sites on a pre-coated Monoclonal antibody spe-
ciﬁc to RANKL. Excess conjugate and unbound sample or
standard are washed from the plate. Next, Avidin conjugated
to Horseradish Peroxidase (HRP) is added to each microplate
well and incubated. Then a TMB substrate solution is added to
each well. The enzyme-substrate reaction terminated by the
addition of a sulfuric acid solution and the color change is
measured spectrophotometrically at a wavelength of
450 nm ± 2 nm. The concentration of RANKL in the samples
is then determined by comparing the O.D. of the samples to
the standard curve.
Anteroposterior plain radiographs of both hands and wrists
were done, and scored using the Sharp method [12], joint space
narrowing (JSN) is assessed in 15 joints (ﬁve MCP, four PIP,
CMC 3rd–5th, multangular navicular-lunate and radiocarpal)
Table 1 Demographic and clinical characteristics of the
rheumatoid arthritis (RA) patients.
Rheumatoid arthritis patients (n= 50)
Characteristic Range Mean ± SD
Age (year) 26–65 47.7 ± 10.4
Duration (year) 0.5–20 7.2 ± 4.5
BMI (kg/M2) 20–42.9 26.6 ± 3.9
Sharp score 0–55 19.6 ± 14.4
ESR (mm/1st h) 5–140 36.3 ± 30.1
DAS-28 1.41–7.96 4.6 ± 1.7
HAQ 0–2 1.2 ± 0.6
BMI = body mass index, ESR= erythrocyte sedimentation rate,
DAS = disease activity score, HAQ= health assessment
questionnaire.
Serum levels of osteoprotegerin and RANKL 3for each hand and wrist. Erosion was assessed in 16 joints (ﬁve
MCP, four PIP, IP of the thumbs, 1st MCP, radius and ulna
bones, trapezium and trapezoid as one unit [multangular],
navicular and lunate) for each hand and wrist. The total sharp
score ranges from 0 to 62. Plain radiographs of the dorso-lum-
bar spine were done to all patients to exclude wedge fracture.
Radiographs were examined by a consultant rheumatologist in
a random order. The latter was blinded to patients’ personal
and clinical data at the time of scoring.
Bone mineral density (BMD) was measured for all partici-
pants using dual-energy X-ray absorptiometry (DEXA) at the
proximal femur, lumbar spine (L1–L4), and distal radius. A
trained technician performed all scans using the same Lunar
DEXA machine. The threshold for establishing a diagnosis
of osteoporosis was based on the World Health Organization
(WHO) deﬁnition, i.e., BMDP 2.5 standard deviations below
the young adult mean (or T score 6 2.5). Osteopenia was
deﬁned as BMD 6 1.0 SD and >2.5 SD from this mean,
with low bone mass including all participants with osteopenia
or osteoporosis.
Statistical methods: For statistical analysis, Statistical pack-
age for social science (SPSS) software version 17 was used.
Descriptive analysis of the results in the form of percentage
distribution for qualitative data and minimum, maximum,
mean and standard deviation calculation for quantitative data
was done. Cross tabulation test was performed for comparison
between percentage values, Student’s t-test for comparison
between means of two groups and F-test (One way ANOVA)
for comparison between means of three groups. Pearson’s cor-
relation was done to describe the relationship between two
variables. In all tests: p-value > 0.05 was considered non-sig-
niﬁcant (NS), p< 0.05 as signiﬁcant, p< 0.01 as highly signif-
icant. The Binary logistic regression was used to investigate the
risk factor in RA-induced osteoporosis, as follows: the depen-
dent variable was the presence of osteoporosis and the inde-
pendent variables (predictors) in this study were the age, sex,
BMI, ESR, tender joint count (TJC), swollen joint count
(SJC), HAQ, OPG, RANKL, and the OPG/RANKL ratio.
3. Results
This study was carried out on 50 RA patients and 20 healthy
volunteers as a control group. Demographic and clinical data
for the patients are shown in Table 1. They were 6 males (12%)
and 44 females (88%). The rheumatoid factor was positive in
42 patients (84%), and negative in 8 patients (16%), we mea-
sured anti-CCP in RF ve patients and it was positive in 6/8
patients (75%) and negative in 2 (25%) of the RF ve cases.
The CRP was positive in 35 (70%) and negative in 15 patients
(30%).
Forty-one RA patients were using MTX (82%), ten
patients were using leﬂunomide (20%), twenty-three patients
were using anti-malarials (46%), and twenty-six patients
were using steroids (52%), the cumulative dose of steroids
ranged between 600 and 73,000 mg with a mean of
12463.0 ± 16363.9 mg and the cumulative dose of MTX ran-
ged between 375 and 100,375 mg with a mean of
15310.9 ± 20856.7 mg.
RA patients had a higher incidence of osteoporosis (23/50,
46%) than that in healthy controls (3/20, 15%) (p= 0.001).
The differences between patients and controls as regardsOPG, RANKL, OPG/ RANKL ratio were highly signiﬁcant
which are as follows: OPG (p= 0.001), RANKL
(p= 0.001), OPG/RANKL (p= 0.001) (Table 2 and Fig. 1).
As regards DEXA scan, the difference between patients and
controls in BMD at the forearm was signiﬁcant (p= 0.049),
while it was non-signiﬁcant at L1–4 (p= 0.109), and highly
signiﬁcant at femoral neck (p= 0.008), signiﬁcant at femoral
wards triangle (p= 0.049) and signiﬁcant at the greater tro-
chanter (p= 0.032) (Table 2).
Comparison of age, BMD, OPG, RANKL, and OPG/
RANKL ratio between normal, osteopenic and osteoporotic
RA patients was done. As shown in Table 3, age was the
non-signiﬁcant variant between the three groups (normal-oste-
openic and osteoporotic) of RA patients (p= 0.079), while
BMD at all detected sites was highly signiﬁcant: forearm
(p= 0.001), L1–4 (p= 0.001), femoral neck (p= 0.001),
greater trochanter (p= 0.001) and femoral wards triangle
(p= 0.001). OPG, RANKL, and OPG/RANKL ratio were
signiﬁcant variants between the three groups: OPG
(p= 0.045), RANKL (p= 0.011) and OPG/RANKL ratio
(p= 0.022) (Table 3).
The OPG level insigniﬁcantly correlated with the disease
duration (r= 0.11), BMI (r= 0.13), ESR (r= 0.15) and
DAS-28 (r= 0.11), and negatively with the age (r= 0.12),
Sharp score (r= 0.16), and drugs used: steroids
(r= 0.10), MTX (r= 0.1). The correlation was non-signif-
icant between the OPG level and the BMD in all detected sites
which is as follows: forearm (r= 0.1), L1–4 (r= 0.02), femo-
ral neck (r= 0.2) and ward (r= 0.3).
The RANKL level signiﬁcantly correlated with the age
(r= 0.35, p= 0.012) and Sharp score (r= 0.3, p= 0.035),
and negatively with the BMD (forearm): (r= 0.4,
p= 0.01) and (wards) (r= 0.3, p= 0.03).
The OPG/RANKL ratio non-signiﬁcantly correlated with:
age (r= 0.06), DAS-28 (r= 0.19), BMI (r= 0.13), and nega-
tively with the disease duration (r= 0.12), ESR (r= 0.07),
MTX dose (r= 0.2), steroid dose (r= 0.13) and Sharp
score (r= 0.18). As regards correlation with BMD, OPG/
RANKL ratio had a highly signiﬁcant correlation with the
forearm value (r= 0.4, p= 0.008), highly signiﬁcant correla-
tion with the BMD at the ward (r= 0.4, p= 0.002), signiﬁ-
cant correlation with the values at the femoral neck (r= 0.3,
p= 0.019) and the correlation was non-signiﬁcant with the
BMD at L1–4 (r= 0.2).
Figure 1 Comparison between patients and controls as regards
osteoprotegerin (OPG), RANKL and OPG/RANKL ratio.
Table 2 Comparison between rheumatoid arthritis (RA) patients and controls as regards osteoporosis markers.
Osteoporosis markers Mean ± SD RA patients (N= 50) Controls (N= 20) p-Value Sig.
OPG (pg/ml) 331.2 ± 143.6 540.6 ± 229.4 0.001 HS
RANKL (ng/ml) 4.7 ± 4.2 3.0 ± 3.1 0.001 HS
OPG/RANKL 531.6 ± 149.4 869 ± 1733.8 0.001 HS
DEXA (g/cm2) Forearm 0.56 ± 0.21 0.68 ± 0.27 0.049 S
L1–4 1.02 ± 0.21 1.104 ± 0.13 0.109 NS
Neck 0.86 ± 0.18 0.99 ± 0.17 0.008 HS
Ward 0.71 ± 0.22 0.82 ± 0.13 0.049 S
GT 0.69 ± 0.18 0.79 ± 0.13 0.032 S
Incidence of osteoporosis (23/50, 46%) (3/20, 15%) 0.001 HS
RA: rheumatoid arthritis, OPG: osteoprotegerin, RANKL: receptor activator of the nuclear factor jB ligand, DEXA: dual-energy X-ray
absorptiometry, GT: greater trochanter.
4 S. Fadda et al.Analysis of the binary logistic regression revealed that:
RANKL level (p= 0.036, CI = 1.02–2) was the unique
independent risk factor in the occurrence of RA-induced
osteoporosis (Table 4).
4. Discussion
The skeletal complications of rheumatoid arthritis include
focal bone erosions, juxta-articular osteopenia at sites of active
inﬂammation and systemic osteopenia, resulting in signiﬁcantTable 3 Comparison of age, BMD, OPG, RANKL, and OPG/R
patients.
Feature Mean ± SD Normal (n= 15) Osteopen
Age (year) 41.4 ± 10.5 41.2 ±
DEXA (g/cm2) Forearm 0.7 ± 0.1 0.6 ±
Neck 1.0 ± 0.1 0.9 ±
Ward 0.9 ± 0.2 0.8 ±
L1–4 1.2 ± 0.1 1.1 ±
GT 0.8 ± 0.1 0.74 ±
OPG (pg/ml) 415.2 ± 128.7 324.3 ±
RANKL (ng/ml) 3.2 ± 4.2 3.0 ±
OPG/RANKL 1075.5 ± 123.4 458.4 ±
BMD: bone mineral density, RA: rheumatoid arthritis, OPG: osteoprot
DEXA: dual-energy X-ray absorptiometry, GT: greater trochanter.joint deformity, disability and pain in addition to an increased
risk of bone fractures [13].
Osteoprotegerin (OPG) functions as a trap receptor by
attaching receptor activator nuclear factor jB ligand
(RANKL), which is an important mediator of a bone resorp-
tion and it prevents the attachment to receptor activator
nuclear factor jB (RANK). It was shown that OPG/RANK/
RANKL had a role in not only focal and generalized bone loss
but also in joint inﬂammation pathophysiology in RA [14].
In this study, we had found a decrease of serum OPG and
an increase of serum RANKL in RA patients, and the differ-
ences between patients and controls as regards OPG, RANKL,
and OPG/RANKL ratio were highly signiﬁcant. This agrees
with the study conducted by Xu and co-workers in which 64
Chinese patients with RA and 60 healthy control subjects were
involved. RA group in their study showed signiﬁcantly higher
serum levels of RANKL, lower serum levels of OPG, and
OPG/RANKL ratio compared with healthy controls [8]. Also,
OPG and RANKL were measured in 85 patients (44 with RA,
41 patients with OA) in serum and synovial ﬂuid as well, and it
was reported that, compared with OA, synovial level of OPG
was signiﬁcantly decreased in RA, whereas synovial RANKL
level was increased [15]. Furthermore, in another study, an
increased concentration of RANKL and a decreased concen-
tration of OPG were detected in synovial ﬂuid from RA
patients. The ratio of OPG to RANKL was signiﬁcantly lower
in synovial ﬂuid of RA patients than that in OA [16]. The
study conducted by Vanderborght and co-workers, in which
17 patients with chronic RA, 14 patients with early RA, 8ANKL ratio between normal, osteopenic and osteoporotic RA
ia (n= 12) Osteoporosis (n= 23) p-Value Sig.
8.1 47.9 ± 10.7 0.079 NS
0.2 0.4 ± 0.2 0.001 HS
0.2 0.8 ± 0.2 0.001 HS
0.2 0.6 ± 0.2 0.001 HS
0.1 0.9 ± 0.2 0.001 HS
0.16 0.57 ± 0.15 0.001 HS
140.3 241.03 ± 123.04 0.045 S
2.8 6.6 ± 4.2 0.011 S
109.6 138.5 ± 163.1 0.022 S
egerin, RANKL: receptor activator of the nuclear factor jB ligand,
Table 4 Binary logistic regression for predictors of osteoporosis in rheumatoid arthritis patients.
Variable B T p-Value 95%CI R2 F p-Value
Dependent Independent
Osteoporosis Age 0.01 2.23 0.136 1.01–1.40 0.46 3.3 0.036
Sex 0.53 0.10 0.747 0.02–14.45
BMI 0.14 0.80 0.370 0.64–1.18
ESR 0.03 1.98 0.159 0.99–1.08
TJC 0.05 0.61 0.433 0.85–1.07
SJC 0.07 0.64 0.425 0.77–1.12
HAQ 1.42 3.18 0.074 0.87–19.63
OPG 0.00 0.98 0.323 0.99–1.00
RANKL 0.36 4.41 0.036 1.02–2.00
OPG/RANKL 0.17 4.45 0.053 1.00–1.1
BMD: bone mineral density, ESR: erythrocyte sedimentation rate, TJC: total joint count, SJC: swollen joint count, HAQ: health assessment
questionnaire, OPG: osteoprotegerin, RANKL: receptor activator of the nuclear factor jB ligand.
Serum levels of osteoprotegerin and RANKL 5patients with OA, and 17 healthy controls were enrolled, also
indicated that RANKL mRNA levels were signiﬁcantly higher
in peripheral blood of patients with early and chronic RA
compared to healthy controls, while OPG mRNA levels were
lower [17]. In another work on Egyptian juvenile idiopathic
arthritis (JIA) cases, there was also an agreement to the ﬁnd-
ings of this study as the serum OPG level was signiﬁcantly
lower, the serum RANKL signiﬁcantly increased and the
OPG/RANKL ratio was signiﬁcantly lower compared to the
control [18]. These data disagree with the study conducted
by Ziolkowska and co-workers in which sera were obtained
from 43 RA patients and from 30 healthy individuals, and
synovial ﬂuids (SF) were obtained from 29 RA patients and
15 patients with OA. This study reported signiﬁcantly higher
serum OPG and RANKL levels, and much higher levels of
OPG and RANKL in synovial ﬂuid in RA [19]. Taken
together, it can be seen from these researches that ﬁndings of
raised serum RANKL and consequent reduction of OPG/
RANKL ratio in RA were identical all the time, although
results of OPG were contradictory, the fact that OPG and
RANKL behave differently and depending on the cells which
produce them which could probably account for the cause of
this discrepancy. It has been suggested again that the OPG/
RANKL ratio may be more important than single OPG or
RANKL in regulating osteoclast formation and regulating
bone destruction in RA [20,21]. These differences may be
explained also by that: age range, sample size, disease severity,
and disease duration are not necessarily comparable between
the studies.
In the present study, it has been observed that the incidence
of RA-induced osteoporosis was 46%, which was 3 times as
high as that in normal individuals. This was similar to Hauge-
berg and co-workers who enrolled 394 RA patients in their
study and reported for the ﬁrst time; the overall frequency of
osteoporosis was doubled in the female RA population [22].
In this study, BMD values in RA were obviously lower than
that in controls at positions of all the detected regions.
Changes of overall bone mass in this study were similar to
the results of other researches [23–25].
In the current study, a signiﬁcant correlation was found
between the age and RANKL level, and this agrees with
Wisowska et al. who reported that the level of OPG and
RANKL was relevant to the patient’s age [26].A signiﬁcant correlation was present between the Sharp
score and RANKL level and this agrees with Geussens et al.
who reported that a signiﬁcant negative correlation with 5-year
radiographic progression was found with the ratio of OPG to
RANKL (r= 0.38; p= 0.001) [27]. There is a signiﬁcant
negative correlation between serum RANKL levels and
BMD and this observation was also reported by Oelzner and
co-workers who found only in RA patients older than 60 years
old, that the serum RANKL levels showed a negative correla-
tion with BMD at the lumbar spine while serum OPG levels or
OPG/RANKL ratio did not relate to BMD [24].
A signiﬁcant correlation between OPG/RANKL ratio and
BMD was also found in the present study. This agrees with
a study that enrolled 30 postmenopausal healthy women, 30
with postmenopausal osteoporosis and 30 with postmeno-
pausal RA; a signiﬁcant correlation was detected between bone
densities of lumbar spine (LS) and femur neck (FN) with the
OPG/RANKL ratio in patients with postmenopausal RA.
Also, a negative correlation was detected between LS and
FN bone densities and RANKL levels [23].
There was a non-signiﬁcant correlation between OPG,
RANKL, OPG/RANKL ratio and disease activity parameters
such as DAS-28 and ESR. This agrees, in part, with the study
conducted by Ghorbanihaghjo who found a non-signiﬁcant
correlation between the OPG level and the DAS28 [28]. More-
over, it was also found in our study that serum concentrations
of OPG, RANKL, and OPG/RANKL ratio were signiﬁcantly
different among groups of normal, osteopenia, and osteoporo-
sis in RA.
Multiple regression analysis for these different parameters
revealed that RANKL level is the unique predictive factor in
RA-induced osteoporosis, and to our knowledge, no previous
research reported this information. In the study on Egyptian
children with JIA, they found that RANKL and OPG/
RANKL ratio were independent predictors of juxta-articular
osteoporosis [18].
In conclusion, although this study is somewhat limited in
statistical power and further studies with a greater number
of patients are needed, our data showed that the OPG/
RANKL system represents an important mediator of bone
resorption in RA-induced osteoporosis. Therefore, targeting
the RANK–RANKL–OPG system may be effective in pre-
venting bone damage in patients with rheumatoid arthritis.
6 S. Fadda et al.Conﬂict of interest
All the authors declare no conﬂict of interest.
References
[1] Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF,
et al. Osteoprotegerin reduces osteoclast numbers and prevents
bone erosion in collagen-induced arthritis. Am J Pathol
2002;161:1419–27.
[2] Abu-Amer Y, Abbas S, Hirayama T. TNF receptor type I
regulates RANK ligand expression by stromal cells and modulates
osteoclastogenesis. J Cell Biochem 2004;93:980–9.
[3] Hofbauer LC, Heufelder AE. The role of osteoprotegerin and
receptor activator of nuclear factor jB ligand in the pathogenesis
and treatment of rheumatoid arthritis. Arthritis Rheum
2001;44:253–9.
[4] Saidenberg-Kermanac’h N, Corrado A, Lemeiter D, deVernejoul
MC, Boissier MC, Cohen-Solal ME. TNF-alpha antibodies and
osteoprotegerin decrease systemic bone loss associated with
inﬂammation through distinct mechanisms in collagen-induced
arthritis. Bone 2004;35:1200–7.
[5] Khosla S. Minireview: the OPG/RANKL/RANK system. Endo-
crinology 2001;142:5050–5.
[6] Page G, Miossec P. RANK and RANKL expression as markers
of dendritic cell-T cell interactions in paired samples of rheuma-
toid synovium and lymph nodes. Arthritis Rheum
2005;52:2307–12.
[7] Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and
pharmacological inhibitor of bone resorption. Curr Pharm Des
2001;7:613–35.
[8] Xu S, Wang Y, Lu J, Xu J. Osteoprotegerin and RANKL in the
pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheu-
matol Int 2012;32:3397–403.
[9] Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham
3rd CO, et al. Rheumatoid arthritis classiﬁcation criteria: an
American College of Rheumatology/European league against
rheumatism collaborative initiative. Ann Rheum Dis
2010;69:1580–8.
[10] El Meidany Y, El Gaafary M, Ahmed I. Cross-cultural adapta-
tion and validation of an Arabic Health Assessment Question-
naire for use in rheumatoid arthritis patients. Joint Bone Spine
2003;70:195–202.
[11] Aletaha D, Smolen JS. The Simpliﬁed Disease Activity Index
(SDAI) and the Clinical Disease Activity Index (CDAI). A review
of their usefulness and validity in rheumatoid arthritis. Clin Exp
Rheumatol 2005;23(5 Suppl. 39):S100–8.
[12] Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett
M, et al. How many joints in the hands and wrists should be
included in a score of radiologic abnormalities used to assess
rheumatoid arthritis? Arthritis Rheum 1985;28(12):1326–35.
[13] Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalized
bone loss in patients with rheumatoid arthritis. Lancet
1994;344:23–7.
[14] Vega D, Maalouf NM, Sakhaee K. The role of receptor activator
of nuclear factor-kB (RANK)/RANK ligand/osteoprotegerin:
clinical implications. J Clin Endocrinol Metab
2007;92(12):4514–21.
[15] Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G,
Klingler A. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial ﬂuid. A comparison of
patients with longstanding rheumatoid arthritis and osteoarthritis.
Rheumatol Int 2005;26(1):63–9.
[16] Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E,
et al. Activated human T cells directly induce osteoclastogenesis
from human monocytes: possible role of T cells in bone
destruction in rheumatoid arthritis patients. Arthritis Rheum
2001;44(5):1003–12.
[17] Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J,
Stinissen P. Osteoprotegerin and receptor activator of nuclear
factor-kappaB ligand mRNA expression in patients with rheu-
matoid arthritis and healthy controls. J Rheumatol
2004;31(8):1483–90.
[18] Alkady EAM, Rashad SM, Khedr TM, Mosad E, Abdel-Wahab
N. Early predictors of increased bone resorption in juvenile
idiopathic arthritis: OPG/RANKL ratio, as a key regulator of
bone metabolism. Egypt Rheumatol 2011;33(4):217–23.
[19] Ziolkowska M, KurowskaM, Radzikowska A, Luszczykiewicz G,
Wiland P, Dziewczopolski W, et al. High levels of osteoproteg-
erin and soluble receptor activator of nuclear factor kappa B
ligand in serum of rheumatoid arthritis patients and their
normalization after anti-tumor necrosis factor alpha treatment.
Arthritis Rheum 2002;46(7):1744–53.
[20] Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay
DM. Osteoprotegerin and receptor activator of nuclear factor
kappa B ligand (RANKL) regulate osteoclast formation by cells
in the human rheumatoid arthritic joint. Rheumatology (Oxford)
2001;40(6):623–30.
[21] Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka
M. Mechanism of hypercalcemia in adult T-cell leukemia:
overexpression of receptor activator of nuclear factor jB ligand
on adult T-cell leukemia cells. Blood 2002;99:634–40.
[22] Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in
patients with active early rheumatoid arthritis: inﬂiximab and
methotrexate compared with methotrexate treatment alone.
Explorative analysis from a 12-month randomised, double-blind,
placebo controlled study. Ann Rheum Dis 2009;68(12):1898–901.
[23] C¸akırca G, Mete N, Batmaz I, Sarıyıldız MA, Mehmet Ali Ulu
MA, Yazmalar L, et al. The relationship between bone mineral
density and levels of RANKL, osteoprotegerin and cathepsin-K in
patients with rheumatoid arthritis. Dicle Tıp Derg
2012;39(4):479–84.
[24] Oelzner P, Franke S, Lehmann G, Eidner T, Mu¨ller A, Wolf G,
et al. Soluble receptor activator of NF kappa B-ligand and
osteoprotegerin in rheumatoid arthritis - relationship with bone
mineral density, disease activity and bone turnover. Clin Rheu-
matol 2007;26(12):2127–35.
[25] Gheita T, Fawzy S, Rizk A, Hussein H. Impaired bone formation
and osteoporosis in postmenopausal elderly onset rheumatoid
arthritis patients. Egypt Rheumatol 2011;33(3):155–62.
[26] Wisowska M, Jakubicz D, Olczyk-Wrochna K. The role of OPG/
RANKL/RANK in bone destruction in rheumatoid arthritis.
Reumatologia 2009;47(2):67–74.
[27] Geusens PP, Landewe RB, Garnero P, Chen D, Dunstan CR,
Lems WF, et al. The ratio of circulating osteoprotegerin to
RANKL in early rheumatoid arthritis predicts later joint destruc-
tion. Arthritis Rheum 2006;54(6):1772–7.
[28] Ghorbanihaghjo A, Hajialilo M, Shahidi M, khabazi A, Kolahi S,
Nakhjavani MRJ et al. Osteoprotegerin (OPG) and matrix Gla
protein (MGP) in rheumatoid arthritis patients: Relation to
disease activity. Egypt Rheumatol 2014;36(3):111–16.
